Table 3 Potential prognostic factors using univariate analysis
Characteristics | Patients (n =) | Mean survival (mths) | P Value* |
|---|---|---|---|
Gender | |||
Male | 63 | 36.42 (31.77–41.08) | 0.8860 |
Female | 28 | 37.08 (30.73–43.44) | |
TNM stage | |||
I | 40 | 41.61 (37.35–45.87) | 0.0005 |
II | 20 | 38.44 (31.18–45.70) | |
IIIa | 28 | 30.31 (22.76–37.86) | |
IIIb | 1 | 6.00 (6.00-6.00) | |
IV | 2 | 13.50 (3.11–23.89) | |
Grade of differentiation | |||
Well | 32 | 37.43 (31.17–43.69) | 0.4984 |
Moderate | 48 | 34.76 (29.86–39.67) | |
Poor | 11 | 39.73 (28.34–51.12) | |
Nodal status | |||
N (-) | 49 | 41.04 (36.64–45.45) | 0.0051 |
N (+) | 42 | 31.25 (25.64–36.86) | |
Vessel cancer embolus | |||
V (-) | 67 | 37.50 (33.41–41.58) | |
V (+) | 24 | 33.89 (25.75–42.03) | |
Postoperative adjuvant therapy | |||
No | 26 | 37.47 (29.70–45.24) | 0.7225 |
Chemotherapy or Radiation | 65 | 36.03 (31.57–40.49) | |
MVD | |||
High MVD | 39 | 31.85 (25.68–38.03) | 0.0434 |
Low MVD | 52 | 39.96 (35.48–44.44) | |
PlGF staining | |||
Low expression | 56 | 40.68 (36.70–44.66) | 0.0028 |
Over expression | 35 | 27.76 (21.17–34.34) |